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Abstract
Menthol contributes to poor cessation rates among smokers, in part because menthol enhances nicotine reward and
reinforcement. Mentholated tobacco products contain ()-menthol and ()-menthol, in varying proportions. We examined
these twomenthol stereoisomers for their ability to upregulate 42 nAChRs and to alter dopamine neuron firing frequency
using long-term, low-dose (500 nM) exposure that is pharmacologically relevant to smoking. We found that ()-menthol
upregulates 42 nAChRs while ()-menthol does not. We also found that ()-menthol decreases dopamine neuron
baseline firing anddopamineneuron excitability,while ()-menthol exhibits no effect.We thenexaminedboth stereoisomers
for their ability to inhibit 42 nAChR function at higher concentrations (10 M) using the Xenopus oocyte expression
system. To probe for the potential binding site of menthol, we conducted flooding simulations and site-directed mutagen-
esis. We found that menthol likely binds to the 9´ position on the TM2 (transmembrane M2) helix. We found that menthol
inhibition is dependent on the end-to-end distance of the side chain at the 9´ residue. Additionally, we have found that
()-menthol is onlymodestly (25%)more potent than ()-menthol at inhibitingwild-type 42 nAChRs and a series of L9´
mutant nAChRs. These data reveal that menthol exhibits a stereoselective effect on nAChRs and that the stereochemical
effect ismuch greater for long-term, submicromolar exposure inmice than for acute, higher-level exposure.We hypothesize
that of the two menthol stereoisomers, only ()-menthol plays a role in enhancing nicotine reward through nAChRs on
dopamine neurons.
Key words: cigarettes; electronic nicotine delivery systems; nicotine; nicotine addiction; Xenopus oocyte
Significance Statement
Menthol is themost popular flavor used in all forms of tobacco products. Depending on themethod used to produce
the menthol, these products contain two stereoisomers [()-menthol and ()-menthol] in unregulated and poorly
characterized amounts. We studied how these isomers of menthol differ in their ability to alter nicotinic receptors on
dopamine neurons that contribute to tobacco addiction. Long-term treatment with ()-menthol and ()-menthol
resulted in a stereospecific effect on nicotinic receptor upregulation and dopamine neuron excitability: ()-menthol
exhibited no effect while ()-menthol exhibited a robust effect. In acute treatments, we found only slight differences
between the effects of the two isomers on nicotine receptors. This suggests that long-term exposure to ()-menthol
may contribute to exacerbating tobacco addiction.
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Introduction
Menthol cigarettes are used by a third of smokers and
by the majority of African-American smokers (McCarthy
et al., 1995). Smokers of menthol cigarettes are less likely
to quit when compared with smokers of nonmenthol cig-
arettes (Ahijevych and Garrett, 2010). Youth smokers of
menthol cigarettes are twice as likely to become lifelong
smokers compared with youth smokers of nonmenthol
cigarettes (D’Silva et al., 2012). Menthol is present in
much of the electronic nicotine delivery system (ENDS)
market (Centers for Disease Control and Prevention,
2016). Some countries, as well as some municipalities in
the United States, ban menthol in combustible tobacco
products. Apart from these exceptions, menthol holds a
unique position as a tobacco flavoring: it is the only flavor
allowed in combustible cigarettes in the United States
following the 2009 Family Smoking Prevention and To-
bacco Control Act.
Recent investigations of menthol identified pharmaco-
logical effects on several members of the Cys-loop family
of receptors: menthol is (1) a negative allosteric modulator
of 42 nAChRs, (2) a noncompetitive antagonist of 7
and 34 nAChRs, (3) a noncompetitive antagonist of
5-HT3 receptors, (4) a positive allosteric modulator of
GABAA receptors, and (5) a positive modulator of glycine
receptors (Hall et al., 2004; Hans et al., 2012; Ashoor
et al., 2013a, b; Lau and Vaughan, 2014; Ton et al., 2015).
While most investigations examined ()-menthol only,
one identified a difference in the actions of ()-menthol
and ()-menthol (Hall et al., 2004). Hall et al. (2004) ob-
served that ()-menthol is a potent allosteric potentiator
of GABAA-mediated currents, while ()-menthol provided
a modest enhancement.
Eight stereoisomers of menthol exist. Plants produce
mainly the stereoisomer [1R, 2S, 5R or ()-menthol; Chen
et al., 2011); but small quantities of additional stereoiso-
mers occur in various types of mint leaves or in the
extracted oil). As with many popular natural products,
demand for menthol greatly exceeds the supply that can
be obtained from plants. In the past, the primary synthetic
method for producing menthol used hydrogenation of
pulegone, producing menthol as a racemate [()-menthol
and ()-menthol; Sell, 2006]. However, Ohkuma et al.
(2000) developed an asymmetric synthesis method that
provides pure ()-menthol. Thus, while ()-menthol and
()-menthol are easily produced synthetically and have
been found in menthol tobacco products (Heck, 2010),
()-menthol has now become the primary stereoisomer in
tobacco products (Chen et al., 2011).
Previous data show that menthol by itself upregulates
nAChRs (Alsharari et al., 2015; Henderson et al., 2016)
and alters midbrain dopamine (DA) neuron firing (Hender-
son et al., 2016). Because both ()-menthol and ()-
menthol may be present in menthol cigarettes, we
investigated the potential differences that these two ste-
reoisomers may exhibit on nAChR upregulation and do-
pamine neuron firing. We show that only ()-menthol is
responsible for the upregulated 42 nAChRs and de-
creased dopamine neuron firing frequency found when
neurons are treated with ()-menthol. We also found that
()-menthol is 25% less potent at inhibiting 42
nAChRs. The concentrations of menthol that inhibit 42
nAChRs are similar to the concentrations required to ac-
tivate the TRPM8 (transient receptor potential cation
channel subfamily M member 8) channel, which is mainly
responsible for the cooling sensation elicited by menthol
(Ha et al., 2015). We also investigated a putative binding
site for menthol on 42 nAChRs using computational
modeling and site-directed mutagenesis. Here we deter-
mined that menthol likely binds to the 9´ site of the trans-
membrane M2 (TM2) helix of 4 nAChR subunits, and its
binding interaction depends on steric interactions. To-
gether, these data show that menthol exhibits different
actions when applied in the long term or acutely. Long-
term exposure to menthol exhibits a stereospecific effect
on nAChR upregulation and dopamine neuron excitability:
()-menthol produces a robust effect, and ()-menthol
seems to be inert. This suggests that ()-menthol, and not
()-menthol, possesses the potential risk of enhancing
nicotine reward and reinforcement.
Materials and Methods
Reagents
()-Menthol (product number 63658), ()-menthol
(product number M2780), and ACh chloride (product
number A6625) were obtained from Sigma-Aldrich.
Mice and cultured midbrain neurons
In electrophysiological experiments, we used pregnant
female Gene Expression Nervous System Atlas tyrosine
hydroxylase (TH)-eGFP mice (Henderson et al., 2016,
2017) that were purchased from the Mutant Mouse Re-
gional Resource Center (Chapel Hill, NC). All experiments
were conducted in accordance with the guidelines for the
care and use of animals provided by the National Insti-
tutes of Health, and protocols were approved by the
Institutional Animal Care and Use Committee at the Cal-
ifornia Institute of Technology. To culture primary mid-
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brain neurons from the TH-eGFP mice, we used
embryonic day 14 embryos. We did not determine the sex
of the embryos; but, given the mixed population of males
and females in litters, the resulting midbrain cultures were
composed of neurons from both sexes. (without deter-
mining their sex). Ventral midbrain tissue was dissected
and cultured using previously published procedures
(Srinivasan et al., 2016). Following digestion with papain
(15 min at 37°C), cells were separated by DNase treat-
ment and trituration, and were plated at a density of
100,000 cells/dish in poly-L-ornithine- and laminin-coated
imaging dishes containing Neurobasal medium supple-
mented with B27, Glutamax, 1% hyclone equine serum,
and 100 M ascorbate. For drug treatments, control me-
dium (control), 500 nM ()-menthol, or 500 nM ()-menthol
were added to the cultures for 10 d. Culture medium was
changed at 3 d intervals.
Neuro-2a cell culture and transient transfections
Neuro-2a cells were cultured using standard tech-
niques (Srinivasan et al., 2011). For imaging, cells were
plated by adding 90,000 cells to poly-D-lysine-coated 35
mm glass-bottom imaging dishes (MatTek) and cultured
in a humidified incubator (37°C, 95% air, 5% CO2). Cells
were transfected as described previously (Henderson
et al., 2014). Similar to previous assays (Henderson et al.,
2016), drug treatments (control or 500 nM menthol stereo-
isomers) were applied for 24 h. Culture medium contain-
ing menthol was removed 1 h before the total internal
reflection fluorescence microscopy (TIRFM) assays and
replaced with extracellular solution (ECS), identical to
methods previously described (Henderson et al., 2016,
2017).
Total internal reflection fluorescence microscopy
TIRFM enables the visualization of fluorescently labeled
intracellular molecules on or near the plasma membrane
(within 250 nm of the cell–coverslip interface). Cultured
neuro-2a cells were imaged live at 37°C in a stage-
mounted culture dish incubator (Warner Instruments) us-
ing methods and instrumentation reported previously
(Richards et al., 2011; Henderson et al., 2014). For each
TIRFM session, image analysis was started 25 h after the
beginning of drug treatment (24 h for drug treatment, 1 h
for washout with ECS). This ensured that each session
recorded cells at the same time point. For each session
and each drug condition, 30–40 cells were imaged. Each
condition was measured in at least three separate imag-
ing sessions.
Patch-clamp electrophysiology
Neurons were visualized with an upright microscope
(BX50WI, Olympus) using near-infrared or blue illumina-
tion (the latter for visualizing GFP fluorescence). Whole-
cell patch-clamp techniques were used to record
electrophysiological signals. Data were sampled at 10
kHz and filtered at 2 kHz. Patch electrodes had a resis-
tance of 4–8 M, when filled with intracellular solution (in
mM: 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10
HEPES, 2 Mg-ATP, and 0.1 GTP). The ECS was com-
posed as follows (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1
MgCl2, 10 HEPES, and 10 glucose. The pH of these
solutions was adjusted to 7.2 with Tris-base, and their
osmolarity was adjusted to 300 mOsm with sucrose.
All recordings were performed at a mean temperature
of 32 1°C. ACh (300 M) was puffed onto neurons using
a Picospritzer III for a duration of 300 ms (holding levels:
voltage clamp, 65 mV; current clamp, 0 pA). Neurons
were selected by the presence or absence of TH-eGFP
fluorescence and labeled as putative DA or GABA neu-
rons. Firing frequency and action potential duration were
recorded (1 min) to further verify GFP or non-GFP dis-
tinctions of DA or GABA neurons. Drug treatments for
cultured midbrain neurons were performed for 10 d (con-
trol or 500 nM either menthol stereoisomer; as described
above). At the beginning of a recording session, dishes
containing cultured midbrain neurons were rinsed with
ECS to remove any remaining drug treatment. Cultured
neurons were placed on the recording stage and perfused
with ECS for 1 h to ensure that all remaining menthol from
chronic treatments was removed. For all recording ses-
sions, perfusion rates were maintained at constant flow so
that changes in agonist washout did not complicate data
interpretation.
Oocyte preparation and injection
Rat 4 and 2 nAChR subunits were in pGEMhe vec-
tors. The mRNAs were prepared from linearized DNA,
using a T7 mMessage mMachine kit (Ambion) and were
purified with the RNeasy Mini Kit (Qiagen). Xenopus laevis
stage V and VI oocytes were harvested via standard
protocols (Marotta et al., 2014). The 4 and 2 mRNAs
were mixed in a 1:10 ratio by mass to obtain the (4)2(2)3
or in a 10:1 ratio to obtain the (4)3(2)2 receptor. For
unnatural amino acid incorporation, a TAG codon was
incorporated into the site of interest, and 40 ng of unnat-
ural amino acid-coupled THG73 tRNA was added to the
injection solution. The 4 and 2 mRNAs were mixed in a
100:1 ratio by mass to obtain the (4)3(2)2 receptor for
these unnatural amino acid experiments. A total of 50 nl of
the RNA mixture were injected into each oocyte, deliver-
ing an mRNA mass total of 22 ng. After injection, the
oocytes were incubated at 18°C in ND96 medium (see
below) enriched with theophylline, sodium pyruvate, and
gentamicin for 48 h before recording.
Oocyte electrophysiology
The OpusXpress 6000A (Molecular Devices) in two-
electrode voltage-clamp mode was used for all electro-
physiological recordings. ACh was dissolved to 1 M stock
solutions in ND96 Ca2-free buffer (96 mM NaCl, 2 mM
KCl, 1 mM MgCl2, and 5 mM HEPES at pH 7.5). The
holding potential was set to 60 mV, and the running
buffer used was ND96 Ca2-free solution for all experi-
ments. All drugs were applied as a 1 ml application in
ND96 Ca2 buffer. Drug applications used 1 ml of drug
solution applied over 15 s followed by a 5 min buffer wash
at a rate of 3 ml/min. Data were sampled at 50 Hz and
then low-pass filtered at 5 Hz. Averaged and normalized
data were fit to one Hill term to generate EC50, IC50, and
Hill coefficient (nH) values. All currents for the activity
testing were normalized to the maximum current pro-
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duced by the oocyte for a given compound (Imax) from
ACh potentiation. The efficacy of compounds was mea-
sured as the ratio of the Imax of the compound divided by
the Imax of the ACh. Error bars represent SEM values.
Molecular dynamics simulations
To characterize putative binding sites of menthol to the
human 42 nicotinic receptor, flooding simulations were
performed using NAMD 2.12 (Phillips et al., 2005). Flood-
ing simulations are molecular dynamics (MD) simulations
in which many identical molecules are initially placed in
solution and allowed to diffuse and interact with the var-
ious environments such as water, membrane, and pro-
teins.
For the protein structure, we used the x-ray crystal
structure of the human 42 nicotinic receptor (Morales-
Perez et al., 2016; Protein Data Bank code, 5KXI). To
prepare the protein for the simulation, we first used Mod-
Web (Sánchez and Sali, 1998), an automated comparative
protein structure modeling web server, to build the miss-
ing intracellular loops (which connect M3 and M4 helices)
for both 4 and 2 subunits. Then, CHARMM-GUI (Jo
et al., 2008) was used to embed the protein into a 120 
120 Å POPC lipid bilayer in the x–y-plane. The x-ray
crystal structure captures the receptor in its desensitized
state with two nicotine molecules bound to the extracel-
lular domain of the receptor. In our simulation, we did not
include the two bound nicotine molecules. To preserve
the crystallographically captured state of the protein, we
imposed harmonic restraints on backbone atoms over the
course of the simulation. The SOLVATE and AUTOIONIZE
plugins in VMD (Humphrey et al., 1996) were used to
solvate and to ionize the system to an NaCl concentration
of 150 mM, respectively.
We started the flooding simulation with 178 menthol
molecules (corresponding to a concentration of165 mM)
randomly placed in the solution. In our preliminary simu-
lations, the majority of menthol molecules aggregated in
the solution before getting a chance to interact with the
lipid head groups or the protein, an expected outcome
given the highly hydrophobic nature of menthol (logD 	
2.7). To overcome this problem, nonbonded repulsive
energy terms were introduced between the two oxygen
atoms of each pair of menthol molecules (using NBFix
corrections). We chose to decrease the well depth of the
Lennard–Jones potential to 0.10 kcal/mol instead of its
original value of 0.1921 kcal/mol. We also increased the
minimum interparticle distance between each pair of ox-
ygen atoms from two menthol molecules from 3.53 to
12.00 Å. As a result, pairs of menthol molecules were
prevented from aggregating. Given the NAMD cutoff of 12
Å for nonbonded interactions, by using these NBFix cor-
rections, we basically turned off the attraction between
any two oxygen atoms that belong to separate menthol
molecules. The production run was performed for 800 ns.
After the first 350 ns, the majority of menthol molecules
partitioned into the membrane, allowing us to turn off the
NBFix corrections so that multiple menthol molecules
were not prevented from approaching the same binding
site/region on the protein.
The simulations were performed under periodic bound-
ary conditions. Long-range electrostatic interactions were
calculated by the PME (Particle mesh Ewald method;
Darden et al., 1993; Essmann et al., 1995) with one grid
point density per angstrom. Except for the very first phase
of melting the lipid tails, where the NVT (constant temper-
ature, constant volume) ensemble is preferred, the NPT
(constant temperature, constant pressure) ensemble was
used. The constant temperature of 310 K for the system
was provided by coupling it to a heat bath and through
Langevin dynamics for all nonhydrogen atoms with a
Langevin damping coefficient of 5 ps1. For the NPT
simulation, the pressure was kept constant at 1 atmo-
sphere through coupling to a Nosé-Hoover Langevin pis-
ton, with a period of 200 fs and a damping timescale of 50
fs. Time steps of 2 fs were chosen for the simulation. For
the water molecules, the TIP3P model (Jorgensen et al.,
1983) was used. CHARMM36 (Klauda et al., 2010) force
field parameters were used for the protein, ions, and
lipids. For menthol, we used the CHARMM General Force
Field (CGenff; Vanommeslaeghe and MacKerell, 2012; Yu
et al., 2012) charges and parameters, calculated by the
CGenff web interface program (Vanommeslaeghe et al.,
2010, 2012).
Code and software availability
NAMD 2.12 was used for all of the molecular dynamics
simulations, and VMD was used for visualization and
analysis of the simulation results. Both of these software
packages are free and available for all users at https://
www.ks.uiuc.edu/Research/namd/ and at https://www.k-
s.uiuc.edu/Research/vmd/, respectively.
Experimental design and statistical analysis
All results are presented as the mean  SEM, and all
statistical analyses were performed using GraphPad
Prism. For microscopy assays (Fig. 1) and electrophysiol-
ogy using cultured neurons (Figs. 2, 3), we used a power
analysis (GPower software, www.gpower.hhu.de) to de-
termine appropriate sample sizes. In experiments that
involved three or more group comparisons (Figs. 1–3),
data were analyzed using a one-way or a two-way
ANOVA. The choice of a one-way or two-way ANOVA is
listed with the corresponding experiment in the Results
section. When effects were shown to be significant, a post
hoc analysis (Tukey’s test) was performed to compare the
individual group means.
Results
Long-term effects of menthol stereoisomers cause
different effects on 42 nAChR upregulation
A previous report found that ()-menthol alone upregu-
lates 4 and 6 nAChRs in cultured neuro-2a cells and
mouse midbrain dopamine neurons (Henderson et al.,
2016). In the previous report, 500 nM ()-menthol
achieved robust upregulation of 4-SEP2 nAChRs, while
50 nM ()-menthol had no effect (Henderson et al., 2016).
Similar to previous reports (Henderson et al., 2016,
2017), we used a combination of TIRFM and a pH-
sensitive GFP version of 4 nAChR subunits (4-SEP) to
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determine how ()-menthol and ()-menthol may act dif-
ferently to upregulate nAChRs transiently transfected into
neuro-2a cells (Fig. 1). This combination of TIRFM and
SEP-labeled nAChRs has been used previously to study
the upregulation of nAChRs (Srinivasan et al., 2011; Hen-
derson et al., 2014, 2016, 2017). A concentration range of
()-menthol and ()-menthol (0.05–4 M) was used to
treat neuro-2a cells transiently transfected with 4-SEP
and 2 nAChR subunits for 24 h before imaging sessions.
The upregulation of 42 nAChRs was examined by
quantifying changes in the plasma membrane raw inte-
grated density (PMRID), which indicates a change in the
number of receptors that reside on the PM. With all con-
centrations, ()-menthol neither increased nor decreased
the PMRID of 4-SEP2 nAChRs (Fig. 1). ()-Menthol
produced a significant increase in 4-SEP2 nAChR PM-
RID at concentrations of 0.1, 0.5, and 1 M when com-
pared with control (Fig. 1; p 	 0.03, one-way ANOVA with
post hoc Tukey’s test). The effect of ()-menthol and
()-menthol on 42 nAChR PMRID was significant by
two-way ANOVA (F(1,381) 	 30.3, p 	 0.0001). These
results suggest that the previous effects we observed with
()-menthol (Henderson et al., 2016, 2017) may be pri-
marily mediated by ()-menthol, and not ()-menthol.
Long-term treatment with menthol stereoisomers
causes different effects on dopamine neuron firing
frequency
We previously used whole-cell patch-clamp electro-
physiology to report that long-term treatment of ()-
menthol decreases the baseline firing of midbrain
dopamine neurons in both mouse brain slices and cul-
tured mouse midbrain neurons (Henderson et al., 2016).
To further characterize different effects of menthol stereo-
isomers, we conducted similar studies with cultured
mouse midbrain dopamine neurons treated for 10 d with
()-menthol or ()-menthol (500 nM; Figs. 2, 3). To facili-
tate the identification of midbrain dopamine neurons, we
cultured neurons from TH-eGFP mice (Fig. 2A1–B3; Srini-
vasan et al., 2016; Henderson et al., 2017). The presence
of hyperpolarization-activated inwardly rectifying nonspe-
cific cation current (Ih) and spike duration was also as-
sessed to aid in the identification of dopamine neurons.
For all TH-eGFP-positive neurons (Fig. 2A1–A3), we de-
tected the presence of Ih and spike durations 4 ms.
We examined cultured dopamine neurons for changes
in baseline firing frequency following 10 d of treatment
with either 500 nM ()-menthol or 500 nM ()-menthol (Fig.
2C,D). Control neurons exhibited a mean firing frequency
Figure 1. Chronic exposure of menthol stereoisomers causes different effects on 42 nAChR upregulation. A, Representative TIRFM
images of neuro-2a cells transfected with 4-SEP and 2 nAChR subunits. Menthol stereoisomers (500 nM) were added 24 h before
imaging sessions. Scale bars, 10 m. Each panel image shows representative cells at pH 7.4. B, PMRID was quantified for SEP
nAChRs following treatment with menthol stereoisomers. For each condition, n  30 cells. Data are the mean  SEM. p 
 0.05;
p 
 0.01 (one-way ANOVA with Tukey). Two-way ANOVA, ()-menthol vs ()-menthol, F(1,381) 	 30.34 and p 
 0.0001. Exact p
values are provided in the text.
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of 4.0  0.7 Hz (Fig. 2C). Long-term treatment with ()-
menthol produced a significant decrease in dopamine
neuron mean firing frequency to 1.5  0.3 Hz (p 	 0.04,
one-way ANOVA with Tukey’s test). This change in firing
frequency is similar to the effect we reported following
long-term treatment with ()-menthol (Henderson et al.,
2016). Long-term treatment with ()-menthol did not pro-
duce a significant change in dopamine neuron firing fre-
quency (Fig. 2C,D). We did observe that 20% of neurons
treated with ()-menthol exhibited an increase in firing
Figure 2. Menthol stereoisomers cause different effects on dopamine neuron baseline firing frequency. A1, B1, Representative image
of a TH-positive cultured midbrain dopamine neuron (A1) and a TH-negative putative GABA neuron (B1). Scale bars, 20 m. A2, B2,
Representative waveforms of a TH-positive dopamine neuron with Ih (A2) and a TH-negative putative GABA neuron without Ih (B2). A3,
B3, B4, Representative action potential from cultured dopamine and GABA neurons. C, Baseline firing frequency of TH-positive
dopamine neurons treated with control, ()-menthol, or ()-menthol (500 nM, each) for 10 d. Data are the mean  SEM. p 
 0.05;
p 
 0.01 (one way ANOVA with Tukey). Circles overlaid with bars represent individual recordings that constitute the mean value for
each respective group (n 	 17, 44, and 19 for control, ()-menthol, and ()-menthol, respectively). Exact p values are provided in the
text. Full data are plotted as a scatterplot with mean  SEM values plotted as an overlaid bar chart. D, Representative whole-cell
current-clamp traces for TH-positive dopamine neurons treated with control or menthol stereoisomers. E1–E3, 9% of the ()-menthol-
treated dopamine neurons displayed dramatic variances in firing frequency. E2 and E3 are magnifications of blue and orange boxes,
respectively, in E1.
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Figure 3. Chronic treatment with menthol stereoisomers causes different effects on dopamine neuron excitability. A1, A2, Repre-
sentative image of TH-positive dopamine neuron with a diagram of the typical placement of patch and puffer pipets. B1–B3,
Representative whole-cell current-clamp recordings from TH-positive dopamine neurons treated with control, ()-menthol, or
()-menthol (500 nM each) for 10 d. Arrows indicate a 300 ms application of 300 M ACh to stimulate nAChRs. C1–C3, Mean firing
frequency over time plot of TH-positive dopamine neurons before and after the ACh puff (indicated by arrow). C4, Quantification of
firing frequency of dopamine neurons for the 3 s after ACh puff. Data are the mean  SEM. n 	 5–9 TH-positive dopamine neurons.
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frequency. All neurons exhibiting an increase in firing
frequency were positive for TH-eGFP fluorescence, Ih,
and spike duration 4 ms. Therefore, we are confident
that these neurons are indeed dopamine neurons and not
GABA neurons, which are also present in these cultured
midbrain neuron preparations. Further examination
showed that a few of these neurons (10% of the 20%)
exhibited spontaneous variations in baseline firing fre-
quency (Fig. 2E1–E3).
Long-term treatment with menthol stereoisomers
causes different effects on dopamine neuron
excitability
We previously reported that ()-menthol alters dopa-
mine neuron excitability (Henderson et al., 2016). Dopa-
mine neurons exhibit increases in firing frequency when
exposed to a nAChR agonist (Nashmi et al., 2007; Drenan
Figure 4. Acute applications display only slight pharmacological differences among menthol stereoisomers. A, Concentration–
response curves of ACh on oocytes injected with 4 and 2 nAChR subunits. Injections were biased to assemble high-sensitivity
(4)2(2)3 nAChRs (1:10) or low-sensitivity (4)3(2)2) nAChRs (10:1). B1, B2, Concentration–response curve of menthol stereoisomers
with high sensitivity (4)2(2)3 nAChRs (B1) or low sensitivity (4)3(2)2 nAChRs (B2). C1, C2, Concentration–response curve of ACh
in the absence or presence of ()-menthol or ()-menthol (50 M) with high sensitivity (4)2(2)3 nAChRs (C1) or low sensitivity
(4)3(2)2 nAChRs (C2). Refer to Tables 1–3 for values for Hill coefficient, EC50, and IC50.
Table 1: Concentration–response relationships of ACh on
(4)3(2)2 and (4)2(2)3 nAChRs
nH EC50 (M) n Imax (A)
1:10 (4)2(2)3 1.54  0.08 93.4  3.34 10 0.3 – 1.1
10:1 (4)3(2)2 1.27  0.10 0.62  0.04 15 0.2 – 13.6
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et al., 2008). When menthol is combined with nicotine, it
can potentiate this effect (Henderson et al., 2017). Despite
this, long-term treatment with menthol alone decreased
dopamine neuron excitability (Henderson et al., 2016).
Using similar methods, we investigated both menthol ste-
reoisomers for their ability to alter dopamine neuron ex-
citability. Similar to the previous experiments, we used
TH-eGFP midbrain cultures and treated them for 10 d with
()-menthol or ()-menthol (both at 500 nM). We recorded
dopamine neurons in current-clamp mode and applied a
300 ms puff of 300 M ACh to stimulate nAChRs (Fig. 3).
A concentration of 300 M ACh was selected to stimulate
a peak response from the nAChRs residing on DA neu-
rons. Control dopamine neurons exhibited a transient,
twofold ACh-induced increase in firing frequency that was
similar to previous reports (Henderson et al., 2016; Fig.
3B1,C1). Dopamine neurons exposed to ()-menthol ex-
hibited a similar 1.9-fold transient ACh-induced increase
in firing frequency (Fig. 3B2,C2). In contrast, dopamine
neurons treated with ()-menthol exhibited a consistent
ACh-induced decrease in firing frequency (Fig. 3B3,C3,C4).
When we compared the fold change in firing frequency
following ACh application, we observed a significant ef-
fect of treatment with menthol stereoisomers (one-way
ANOVA, F(2,17) 	 9.96, p 	 0.0014). The change in dopa-
mine neuron firing frequency following long-term treat-
ment with ()-menthol was significant when compared
with both control-treated and ()-menthol-treated dopa-
mine neurons (p 	 0.002 and p 	 0.007, respectively).
These data further support the suggestion that ()-
menthol is the primary mediator for the effects we previ-
ously observed with ()-menthol.
Acute applications of menthol stereoisomers exhibit
similar pharmacologic profiles
Our long-term applications of menthol have studied
submicromolar concentrations that we perceive to be
pharmacologically relevant (Henderson et al., 2016). Pio-
neering observations showed that menthol at higher con-
centrations (100- to 1000-fold greater than the
concentration we use in our long-term studies) acts as a
negative allosteric modulator of 42 nAChRs (Hans
et al., 2012), a noncompetitive antagonist of 34
nAChRs (Ton et al., 2015), and a noncompetitive antago-
nist of 7 nAChRs (Ashoor et al., 2013b). Although the
concentrations used in these studies may not be pharma-
cologically relevant in some cases, this profile suggests
that menthol directly interacts with nAChRs and most
likely at an allosteric site. Using X. laevis oocytes and
two-electrode voltage-clamp electrophysiology, we used
concentration–response assays to examine how acute
applications of ()-menthol and ()-menthol differed in
their ability to act as inhibitors of 42 nAChR function
(Fig. 4).
Long-term treatment with nAChR ligands can change
the stoichiometry of 42 nAChRs. Thus, we studied
menthol inhibition on both the low-sensitivity and high-
sensitivity stoichiometries of 42 nAChRs [(4)3(2)2 and
(4)2(2)3, respectively; Fig. 4]. On both 42 nAChR
stoichiometries, we observed potencies and efficacies for
ACh that are similar to previously reported data (Fig. 4A,
Table 1; Nelson et al., 2003; Tapia et al., 2007). Both
()-menthol and ()-menthol inhibited both stoichiome-
tries of 42 nAChRs (Fig. 4B1,B2, Table 2). ()-Menthol
was modestly more potent at both stoichiometries (p 	
0.033 and p 	 0.0001 for (4)2(2)3 and (4)3(2)2
Table 2 : Concentration–response relationships of menthol stereoisomers on (4)3(2)2 and (4)2(2)3 nAChRs
nH IC50 (M) n Imax (A)
1:10 (4)2(2)3
a
(–)-Menthol 0.71  0.02 44.9  1.62 10 0.08–1.34
()-Menthol 0.90  0.03 48.3  1.67c 10 0.12–0.97
10:1 (4)3(2)2
b
(–)-Menthol 0.81  0.03 33.1  1.83 10 0.09–1.30
()-Menthol 0.85  0.03 45.5  2.03d 10 0.13–1.37
aStimulated with 2 M ACh.
bStimulated with 100 M ACh.
cp 	 0.033, IC50 of ()-menthol vs. ()-menthol on (4)2(2)3 nAChRs.
dp 	 0.0001, IC50 of ()-menthol vs. ()-menthol on (4)2(2)3 nAChRs.
Table 3: Concentration–response of ACh in the absence and presence of menthol stereoisomers on (4)3(2)2 and (4)2(2)3
nAChRs
Receptor nH IC50 (M) n Imax (A)
1:10 (4)2(2)3
a
ACh only 1.27  0.05 0.61  0.0205 15 0.04–1.05
With (–)-menthol 1.38  0.08 0.66  0.0318 12 0.05–0.82
With ()-menthol 1.51  0.10 0.64  0.0321 15 0.03–0.85
10:1 (4)3(2)2
b
ACh only 1.74  0.07 99.8  2.37 19 0.2–13.6
With (–)-menthol 1.58  0.04 120.8  2.37 18 0.1–9.9
With ()-menthol 1.56  0.04 126.4  2.52 19 0.1–9.3
aStimulated with 2 M ACh.
bStimulated with 100 M ACh.
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nAChRs, respectively; Table 2). We also compared ()-
menthol and ()-menthol with regard to competitive ver-
sus noncompetitive actions. Using methods similar to
those of Hans et al. (2012), we used a concentration
response of ACh in the absence and presence of menthol
stereoisomers (50 M) to test whether menthol caused
insurmountable inhibition (a type of noncompetitive inhi-
Figure 5. Snapshots of a menthol molecule during flooding simulation. A, Menthol (shown in green sticks) is introduced in the
extracellular solution. Menthol first encounters the extracellular domain (ECD) of the human 42 nicotinic receptor. B, Menthol binds
to different residues on the ECD. C, Menthol reaches the “top” of the M2 region. D–F, For the rest of the flooding simulation, menthol
remains in the transmembrane domain, between the “top” of the M2 region and the ring of 9´ Leu residues (shown as red sticks).
Menthol does not move toward the cytoplasmic end of M2. The full movie may be downloaded from https://drive.google.com/drive/
folders/1R7PWDpd7QpffZt7r9b3BWlH73WZgNbH0?usp	sharing.
Figure 6. A snapshot of a menthol molecule sitting in the center
of the ring of 9´ leucine residues. The carbons of menthol are
shown in green, its hydrogens in white, and its oxygen in red. The
carbons of the 9´ leucine residues are shown in gray, their
oxygens in red, and their nitrogens in blue. The hydrogens of the
leucine residue are not shown in the figure. The image is a
higher-resolution snapshot from the movie available at https://
drive.google.com/file/d/1eETqhvRk50-UayXNfUG94sHSwxSK6OoC/
view.
Table 4 : IC40 values for ()-menthol on (4[L9´X])2(2)3
mutant nAChRs
Residue IC30 (M ()-menthol  SEM) n
Ala 855  130 18
Ser 357  62.0 11
Gln 117  14.0 13
Thr 547  110 11
Cys 162  23.0 11
Ile 50.1  11.0 7
Met 18.4  1.60 10
Leu (WT) 35.6  5.70 9
Phe 121  10.0 10
Trp 26.6  4.90 10
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bition) or a parallel shift to the right in EC50 (indicative of
competitive inhibition; Fig. 4C1,C2). Here both ()-
menthol and ()-menthol caused a 40% decrease in the
efficacy of ACh with no significant change in EC50
(Table 3, Fig. 4C1,C2). From this, both menthol stereo-
isomers act as noncompetitive inhibitors of 42
nAChRs with similar potency despite the clear differ-
ence we observed with their long-term, low-dose ap-
plications.
Flooding simulations suggest a putative menthol
binding site on 42 nAChRs
As computational resources become more efficient, more
studies are using molecular dynamics to guide experimental
design (Ashoor et al., 2013b; Dalton et al., 2014; Arcario
et al., 2017; Bottaro and Lindorff-Larsen, 2018). We used
“flooding” simulations in which copies of menthol were
added to the solution phase of a simulation system
containing an 42 nAChR (Brannigan et al., 2010).
Most of the menthol molecules partition to the lipid mem-
brane, leaving just a small percentage of the total number of
menthol molecules in the aqueous phase. The protein re-
mained stable throughout the simulation and predicted
binding sites were deemed notable if menthol remained
within 5 Å of the protein for50 ns. Many of these predicted
binding sites were on the periphery of the protein; however,
one was inside the receptor pore (Fig. 5). Specifically, the
site in the pore was the ring of leucines at the 9´ position on
TM2 (Fig. 6). This position is important for modulating the
sensitivity of the protein to agonists without affecting the
agonist-binding site (Labarca et al., 1995; Kearney et al.,
1996; Kosolapov et al., 2000). Based on the simulation and
the importance of the 9´ site, we probed this prediction
further with oocyte expression experiments (Tables 4, 5). We
also probedmany of the other predicted binding sites on the
periphery of the protein, but our results showed that mutat-
ing these sites had no meaningful influence on menthol
potency (Tables 6, 7). Among these mutants, we observed
no detectable currents from (4[E182A])3(2[wt])2, (4[D51A,
E52A])3(2[wt])2, (4[Q55A])3(2[wt])2, (4[I280A])3(2[wt])2, (4
[I226A])3(2[wt])2, (4[L279A])3(2[wt])2, (4[Y283A])3(2[wt])2,
(4[L229A])3(2[wt])2, (4[G281W])3(2[wt])2, (4[E282D])3
(2[wt])2, (4[E282A])3(2[wt])2, and (4[wt])3 (2[I214A])2 when
1 mM ACh was applied. Additionally, IC50 data were not trust-
worthy for ()-menthol for (4[wt])3 (2[G364L])2, (4[wt])3
(2[F306W])2, (4[M288W])3 (2[wt])2, (4[wt])3 (2[M280W])2,
and (4[V356W])3 (2[M368W])2 because currents were too
small for systematic measurements at approximately half-
maximal [ACh]. We did not calculate IC50 values for ()-
menthol for (4[L9´A])3 (2[M368W])2, (4[L9´T])3 (2[wt])2,
(4[L9´A])3 (2[wt])2, 4[L9´A])3 (2[V360W])2, and (4[L9´A])3
(2[F328W])2 because inhibition with ()-menthol was too
weak for systematic fitting to the Hill equation. We probed only
a subset of residueswith ()-menthol for stereoselectivity com-
parison experiments.
The L9´ residue on M2 is important for menthol
inhibition
Based on the simulation results, we made additional mu-
tations to (4)2(2)3 nAChRs at the L9´ site and measured
dose–response relations for ()-menthol using two-
electrode voltage-clamp electrophysiology (Fig. 7). The data
confirmed that menthol block depends on the residue at the
9´ position on the M2 helix in nAChR subunits (Fig. 7).
Further, mutating this position to different amino acids elic-
ited a range of potency for menthol inhibition. The greatest
effect on the ability of menthol to inhibit 42 nAChRs was
observed with the leucine to alanine (L9´A) mutation (Fig.
7A1,A2, Tables 4, 5). The 4[L9´A]2 receptor is 100-fold
less sensitive to menthol block than wild type (WT; Fig. 7B).
At the other extreme of sensitivity, 4[L9´M]2 is more sen-
sitive (10-fold). Based on these results, menthol-induced
inhibition depends strongly on the side chain at the 9´ posi-
tion.
A possible complication is that we tested menthol using
much lower ACh for measurements on the (4[L9´A])3(2)2
receptor than on theWT receptor. This choice was driven by
our desire to test menthol effects at roughly equally effective
[ACh] for each individual receptor combination; the
(4[L9´A])3(2)2 receptor has 10
4-fold lower EC50 values for
ACh when compared with the wild-type receptor (Labarca
et al., 1995; Kearney et al., 1996; Kosolapov et al., 2000;
Dash et al., 2014). Nonetheless, one asks whether one can
treat the menthol block as truly independent of events of the
agonist binding site. To address this issue, we performed
additional experiments using 1 M ACh to activate the WT
and mutant receptors (Fig. 7B). The partially activated WT
receptor is blocked50% by30 M menthol; but the fully
activated (4[L9´A])3(2)2 receptor remains almost com-
pletely unblocked by [menthol] 
1 mM. The data therefore
preserve the concept that menthol exerts a “noncompeti-
tive” block (presumably at the 9´ site in the transmembrane
pore), and this block can be measured over a wide range of
[ACh].
Next, we determined the minimum number of 9´ muta-
tions, within an nAChR pentamer, required to perturb the
activity of menthol. Because the L9´A mutation most drasti-
cally reduced menthol sensitivity, we varied the number of
L9´A mutations within the receptor pentamer. Since nAChRs
are pseudosymmetric with fivefold symmetry, we can make
up to five 9´A mutations. We made mutants with one, two,
and three 9´A mutations since (4[L9´A])3(2)2 proved to be
unaffected by menthol (Fig. 8A). We were also interested in
determining whether this was a subunit-dependent effect,
so we incorporated 9´A mutations in either 2 or 5 nAChR
subunits. In all the mutants tested, as long as there was at
Table 5 : IC30 values for ()-menthol on (4[L9´X])2(2)3
mutant nAChRs
Residue IC30 (M ()-menthol  SEM) n
Ala 760  100 9
Ser 215  41.0 11
Gln 114  12.0 10
Thr 475  47.0 9
Cys 108  28.0 11
Ile 70.4  18.0 9
Met 15.6  5.50 15
Leu (WT) 27.1  4.50 8
Phe 60.0  12.0 8
Trp 11.3  1.60 18
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Table 6: EC50 values for mutant 42 nAChRs
Motivation Mutant EC50 (M ACh)  SEM Hill coefficient  SEM
WT-LS (4[wt])3(2[wt])2 83.4  4.67 0.905  0.03
WT-HS (4[wt])2(2[wt])3 0.924  0.0656 0.924  0.1
WT-5 5[wt](4[wt]2[wt])2 0.409  0.0418 1.06  0.1
9´ residue (4[L9´A])2(2[wt])3 0.499  0.032 1.43  0.1
9´ residue (4[L9´S])2(2[wt])3 0.0356  0.00145 1.29  0.06
9´ residue (4[L9´I])2(2[wt])3 960.  502 0.489  0.03
9´ residue (4[L9´T])2(2[wt])3 0.282  0.0233 1.28  0.1
9´ residue (4[L9´Q])2(2[wt])3 0.530  0.0136 1.284  0.03
9´ residue (4[L9´C])2(2[wt])3 2.68  0.311 0.710  0.1
9´ residue 4[L9´F])2(2[wt])3 0.547  0.0209 1.26  0.05
9´ residue (4[L9´W])2(2[wt])3 0.240  0.00906 1.19  0.05
GABA (4[L376W])3(2[wt])2 247  99.4 0.772  0.1
MD (4[V356A])3(2[wt])2 244  113 0.843  0.2
GABA (4[wt])3(2[M305W])2 180.  38.2 0.938  0.1
MD (4[wt])3(2[W355L])2 171  28.0 1.04  0.1
MD (4[W363L])3(2[wt])2 159  55.2 0.941  0.2
GABA (4[wt])3(2[G364L])2 153  164 0.728  0.3
TRPM8 (4[L383A])3(2[wt])2 150.  7.67 0.919  0.03
TRPM8 (4[wt])3(2[R299A])2 140.  64.7 0.510  0.05
MD (4[I357A])3(2[wt])2 124  19.1 0.957  0.09
MD (4[W363L])3(2[W355L])2 122  11.6 1.31  0.1
GABA (4[wt])3(2[F306W])2 106  12.2 1.07  0.1
ADNFLE (4[S6’F])3(2[wt])2 105  47.5 1.27  0.1
MD (4[F299A])3(2[wt])2 83.2  7.35 1.22  0.1
9´ residue (4[L9´O-Me-Thr])3(2[wt])2 61.3  4.64 1.07  0.07
GABA (4[wt])3(2[L282W])2 77.5  6.44 1.01  0.06
GABA (4[wt])3(2[V360W])2 71.2  5.79 1.24  0.1
GABA (4[M288W])3(2[wt])2 70.8  11.1 0.913  0.1
GABA (4[wt])3(2[M280W])2 57.8  6.94 1.29  0.2
ADNFLE (4[wt])3(2[V287L])2 38.0  23.8 0.493  0.07
Docking (4[G281A, V236A])3(2[wt])2 28.1  4.84 0.998  0.1
Docking (4[wt])3(2[I218A,L257A])2 26.6  3.65 0.862  0.08
Docking  GABA (4[G281A, V236A])3(2[M368W])2 24.3  5.55 0.629  0.07
GABA (4[wt])3(2[Y275W])2 21.1  6.75 0.988  0.1
GABA (4[wt])3(2[M368W])2 1.58  0.508 0.493  0.09
MD  GABA (4[V356W])3(2[M368W])2 1.46  0.219 1.56  0.3
# 9´A 5[V9´A](4[wt]2[wt])2 0.818  0.0178 0.818  0.03
ADNFLE (4[S10’L])3(2[wt])2 0.671  0.112 0.512  0.04
MD  GABA (4[F299W, L376W])3(2[M368W])2 0.511  0.0293 1.39  0.09
MD (4[F299W])3(2[wt])2 0.508  0.0309 1.20  0.07
MD  GABA (4[L376W])3(2[M368W])2 0.504  0.0711 1.41  0.2
9´ residue (4[L9´M])3(2[wt])2 0.503  0.0663 0.585  0.04
MD  GABA (4[F299W])3(2[M368W])2 0.486  0.0434 1.25  0.1
9´ residue (4[L9´M])2(2[wt])3 0.380  0.0307 1.22  0.1
MD (4[V356W])3(2[wt])2 0.360  0.0188 1.65  0.1
9´ residue  GABA (4[L9´A])3(2[M368W])2 0.0230  0.00200 0.900  0.06
# 9´A (4[wt])3(2[L9´A])2 0.0695  0.00353 1.32  0.07
9´ residue (4[L9´T])3(2[wt])2 0.0981  0.00729 0.995  0.06
9´ residue (4[L9´I])3(2[wt])2 160.  50.3 0.866  0.1
9´ residue (4[wt])2(2[L9´A])3 0.0197  0.00163 1.12  0.09
9´ residue (4[L9´A])3(2[wt])2 0.0159  0.000691 1.16  0.05
9´ residue  MD (4[L9´A])3(2[V360W])2 0.00352  0.000290 1.19  0.1
9´ residue  MD (4[L9´A])3(2[F328W])2 0.00318  0.000237 1.13  0.08
ACh Binding Site (4[H116V,Q124F,T126L])3(2[wt])2 76.3  1.85 1.63  0.06
Intra-subunit (4[C233A])3(2[wt])2 143  17.2 0.99  0.08
Intra-subunit (4[T235A])3(2[wt])2 43.6  3.89 1.10  0.09
Intra-subunit (4[V236A])3(2[wt])2 76.2  14.2 1.31  0.3
Intra-subunit (4[G281F])3(2[wt])2 33.5  9.87 1.49  0.6
Intra-subunit (4[S232A])3(2[wt])2 162  20.6 0.993  0.08
Intra-subunit (4[G281A])3(2[wt])2 19.9  1.47 1.49  0.2
Near Cys loop (4[E52L])3(2[wt])2 33.3  2.71 1.27  0.1
Near Cys loop (4[E182Q])3(2[wt])2 63.5  4.54 1.66  0.2
Near Cys loop (4[wt])3(2[S44A])2 86.1  8.21 1.70  0.3
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least one 9´A mutation in 4, 5, or 2 nAChR subunits,
inhibition by 100 M ()-menthol was significantly reduced
(unpaired t test, p 	 0.0001; Fig. 8A). The reduction in the
ability of menthol to inhibit nAChRs that harbor 9´A muta-
tions suggests that menthol binds to this site in TM2.
One bound menthol molecule is sufficient for 42
inhibition
Hill coefficients, which describe the overall steepness
of the concentration–response relation, are often used to
gain an understanding of ligand–receptor binding stoichi-
ometry (Prinz, 2010). We investigated the minimum num-
ber of bound menthol molecules necessary for channel
inhibition. To test this, we calculated the Hill coefficients
for both stereoisomers of menthol on all of the mutants
tested (Fig. 8B). Since the average Hill coefficient is not
significantly different from unity for either ()-menthol or
()-menthol, we concluded that the presence of a single
bound menthol molecule is sufficient for nAChR inhibition.
The activity of ()-menthol and ()-menthol depends
on the end-to-end length of the 9´ residue
Which properties of the side chain at 9´ are important
for the inhibitory activity of menthol on 42 nAChRs? We
examined the IC40 or IC30 values for ()-menthol and
()-menthol, respectively, against the 9´ residue volume,
end-to-end length, and other parameters in the reduced
amino acid index (AA index) (Fig. 9, Fig. 9-1, and Fig. 9-2;
Zamyatnin, 1972; Kibinge et al., 2014). We calculated an
additional parameter, end-to-end residue length, using a
6-31G basis set Hartree–Fock calculation in SPARTAN
’14 (Wavefunction). We choose to use IC40 or IC30 so that
the values calculated remained within the limits of our
experimental data (Fig. 7A1,A2) because many of our
dose–response studied failed to reach 100% inhibition at
1 mM menthol. We obtained a satisfactory relation when
we compared the end-to-end length of residues with the
IC40 of ()-menthol; the correlation coefficient was 0.69
(Fig. 9A1). For ()-menthol (IC30), we observed a correla-
tion coefficient of 0.74 (Fig. 9A2). Thus, the potency of
either stereoisomer of menthol exhibited a strong corre-
lation with residue end-to-end length. We observed sim-
ilar correlations when we compared the IC40 or IC30 of
()-menthol and ()-menthol, respectively, to residue vol-
ume (Fig. 9B1,B2).
Interestingly, previous data show that the EC50 of ago-
nists depends strongly on polarity, a different property of
the side chain at the 9´ position (Kearney et al., 1996;
Kosolapov et al., 2000). To test whether polarity is a
factor for menthol-induced inhibition, we incorporated
O-methyl-threonine (O-Me-Thr) at the 9´ position. The
end-to-end length of O-Me-Thr is just 0.41 Å longer than
isoleucine (3.55 vs 3.14 Å), but because of the oxygen
instead of a methylene unit in the side chain, O-Me-Thr is
substantially more polar than isoleucine. If polarity at the
9´ position is important for menthol inhibition, we would
expect to measure a meaningful difference in the concen-
tration–response curve for menthol inhibition at these two
mutants. We observed that the concentration–response
relationships overlapped when comparing 4[L9´I]2 to its
O-Me-Thr variant (Fig. 9C). This suggests that menthol
inhibition does not depend on the polarity of the 9´ side
chain.
Additionally, we fitted the IC40 or IC30 values for ()-
menthol and ()-menthol, respectively, against the re-
duced AA index (Kibinge et al., 2014). The reduced AA
index is a set of eight indices describing the variability
of amino acids based on experimental results. The
reduced AA index is a subset of the AA index after the
elimination of redundancies. We found that the end-to-
end residue length and residue volume had more mean-
ingful correlations than any parameter in the reduced
AA index.
The two stereoisomers of menthol inhibit 7 nAChRs
with similar IC50 values, but differences have been ob-
served on the GABAA receptors, biomembrane models,
and mouse odorant receptors (Corvalán et al., 2009;
Ashoor et al., 2013b; Takai and Touhara, 2015; Gusain
et al., 2017). To further compare the potency of ()-
menthol and ()-menthol on 42 nAChRs, we compared
the percentage inhibition by 100 M menthol along with
the IC50 and pIC30 values on the 10 (4[L9´X])2(2)3
nAChRs and wild-type (4)3(2)2 nAChR (Fig. 7C,D1,D2).
These scatterplots show either a comparison of the inhi-
bition data (Fig. 7B) or comparison to a logarithmic trans-
formation (Fig. 7D1,D2). We excluded the IC50 values for
(4[L9´A])2(2)3 because we failed to observe inhibition of
50% of the control response. The data extend the exper-
iments on wild-type nAChRs (Fig. 4), which showed mod-
estly less inhibition by the () stereoisomer: ()-menthol
was on average 25% less potent than ()-menthol (Fig.
7D1,D2).
Motivation Mutant EC50 (M ACh)  SEM Hill coefficient  SEM
(4[L265A])3(2[wt])2 26.5  6.58 0.864  0.2
Channel pore (4[wt])3(2[L257A])2 0.316  0.101 1.31  0.4
Interfacial (4[F286A])3(2[wt])2 46.5  8.45 0.962  0.1
Interfacial (4[wt])3(2[I218A])2 119  11.7 1.21  0.1
Interfacial (4[G281A])3(2[I218A])2 23.8  2.28 0.868  0.5
WT-LS, Wild-type 42 receptor with the low sensitivity stoichiometry; WT-HS, wild-type 42 receptor with the high sensitivity stoichiometry; WT-5, wild-
type 42 receptor with 5 in the auxiliary position; 9´ residue, a mutant at the 9´ position to probe the effects of mutations at this site; GABA, analogous site
for the menthol binding site in the GABA receptor; MD, molecular dynamics predicted position; TRPM8, analogous site for the menthol binding site on the
TRPM8 receptor; ANDFLE, a mutant that is found in ADNFLE patients; Docking, position predicted by preliminary docking studies; #L9´A, mutant made to
probe the effects that the number of 9´A mutations has on the effects of menthol; ACh binding site, the putative ACh binding site; Intra-subunit, site between
subunits in the transmembrane domain of 42; Near Cys loop, site that is near the Cys loop of 42; Channel pore, site that is in the channel pore of 42;
Interfacial, a site on the transmembrane domain of a single subunit that faces toward the other transmembrane domain helices on the same subunit.
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Table 7: IC50 values for mutant 42 nAChRs
Motivation Mutant IC50 (M ()-menthol)  SEM Hill coefficient  SEM Maximum inhibition (%)
WT-LS (4[wt])3(2[wt])2 33.7  1.16 0.952  0.04 95
WT-HS (4[wt])2(2[wt])3 33.9  7.40 0.481  0.1 71
WT-5 5[wt](4[wt]2[wt])2 51.0  9.06 0.593  0.2 53
9´ residue (4[L9´A])2(2[wt])3 114  152 0.779  0.2 45
9´ residue (4[L9´S])2(2[wt])3 514  361 0.740  0.1 65
9´ residue (4[L9´I])2(2[wt])3 97.3  38.5 0.836  0.2 79
9´ residue (4[L9´T])2(2[wt])3 717  770. 0.946  0.3 59
9´ residue (4[L9´Q])2(2[wt])3 165  28.1 1.03  0.1 81
9´ residue (4[L9´C])2(2[wt])3 306  173 0.744  0.1 65
9´ residue 4[L9´F])2(2[wt])3 211  75.6 1.01  0.1 72
9´ residue (4[L9´W])2(2[wt])3 28.8  3.26 0.917  0.1 87
GABA (4[L376W])3(2[wt])2 17.4  43.2 2.38  1.6 92
MD (4[V356A])3(2[wt])2 29.6  11.0 0.631  0.2 80
GABA (4[wt])3(2[M305W])2 70.6  29.9 0.872  0.2 90
MD (4[wt])3(2[W355L])2 28.8  24.6 0.589  0.4 80
MD (4[W363L])3(2[wt])2 42.7  9.37 1.02  0.2 96
TRPM8 (4[L383A])3(2[wt])2 27.9  4.97 0.828  0.1 96
TRPM8 (4[wt])3(2[R299A])2 52.0  5.89 1.30  0.2 96
MD (4[I357A])3(2[wt])2 31.4  6.23 1.30  0.3 94
MD (4[W363L])3(2[W355L])2 28.4  6.96 0.866  0.2 91
ADNFLE (4[S6’F])3(2[wt])2 32.3  6.05 1.19  0.3 95
MD (4[F299A])3(2[wt])2 20.4  10.4 0.548  0.2 93
9´ residue (4[L9´O-Me-Thr])3(2[wt])2 135.9  20.9 0.883  0.7 79
GABA (4[wt])3(2[L282W])2 26.1  5.40 0.883  0.1 97
GABA (4[wt])3(2[V360W])2 16.7  1.37 1.08  0.09 96
ADNFLE (4[wt])3(2[V287L])2 17.0  5.67 0.766  0.2 89
Docking (4[G281A, V236A])3(2[wt])2 11.0  0.767 0.958  0.06 96
Docking (4[wt])3(2[I218A,L257A])2 23.0  2.68 1.57  0.3 99
Docking  GABA (4[G281A, V236A])3(2[M368W])2 59.5  15.2 0.891  0.2 95
GABA (4[wt])3(2[Y275W])2 21.7  5.21 1.06  0.2 97
GABA (4[wt])3(2[M368W])2 57.8  8.07 0.865  0.09 93
# 9´A 5[V9´A](4[wt]2[wt])2 1750  3360 0.907  0.3 36
ADNFLE (4[S10’L])3(2[wt])2 29.4  4.32 1.39  0.2 97
MD  GABA (4[F299W, L376W])3(2[M368W])2 107  7.07 1.07  0.06 94
MD (4[F299W])3(2[wt])2 32.5  9.35 0.604  0.09 87
MD  GABA (4[L376W])3(2[M368W])2 107  29.6 0.890  0.2 87
9´ residue (4[L9´M])3(2[wt])2 39.2  7.98 0.848  0.09 83
MD  GABA (4[F299W])3(2[M368W])2 92.5  36.8 0.777  0.2 79
9´ residue (4[L9´M])2(2[wt])3 26.6  1.90 1.04  0.07 91
MD (4[V356W])3(2[wt])2 52.6  43.6 0.599  0.2 70
# 9´A (4[wt])3(2[L9´A])2 1920  9620 0.807  0.6 38
9´ residue (4[L9´I])3(2[wt])2 127  29.1 0.947  0.1 84
9´ residue (4[wt])2(2[L9´A])3 3030  2480 0.832  0.8 31
ACh binding site (4[H116V,Q124F,T126L])3(2[wt])2 64.4  2.09 1.20  0.05 90
Intra-subunit (4[C233A])3(2[wt])2 46.1  6.43 1.53  0.3 98
Intra-subunit (4[T235A])3(2[wt])2 66.6  8.03 1.60  0.3 97
Intra-subunit (4[V236A])3(2[wt])2 58.9  10.0 1.79  0.4 91
Intra-subunit (4[G281F])3(2[wt])2 108  19.1 1.14  0.2 99
Intra-subunit (4[S232A])3(2[wt])2 92.0  26.7 1.64  0.7 92
Intra-subunit (4[G281A])3(2[wt])2 25.6  1.43 1.49  0.1 99
Near Cys Loop (4[E52L])3(2[wt])2 22.7  1.67 0.969  0.07 96
Near Cys loop (4[E182Q])3(2[wt])2 24.3  0.593 1.23  0.04 81
Near Cys loop (4[wt])3(2[S44A])2 59.9  5.09 2.74  0.6 94
Channel pore (4[L265A])3(2[wt])2 21.1  3.06 1.16  0.2 97
Channel pore (4[wt])3(2[L257A])2 74.8  15.6 1.36  0.3 98
Interfacial (4[F286A])3(2[wt])2 54.2  19.9 0.927  0.3 87
Interfacial (4[wt])3(2[I218A])2 60.9  7.63 1.12  0.1 99
Interfacial (4[G281A])3(2[I218A])2 23.8  1.58 2.25  0.3 99
WT-LS, Wild-type 42 receptor with the low sensitivity stoichiometry; WT-HS, wild-type 42 receptor with the high sensitivity stoichiometry; WT-5, wild-
type 42 receptor with 5 in the auxiliary position; 9´ residue, a mutant at the 9´ position to probe the effects of mutations at this site; GABA, analogous site
for the menthol binding site in the GABA receptor; MD, molecular dynamics predicted position; TRPM8, analogous site for the menthol binding site on the
TRPM8 receptor; ANDFLE, a mutant that is found in ADNFLE patients; Docking, position predicted by preliminary docking studies; #L9´A, mutant made to
probe the effects that the number of 9´A mutations has on the effects of menthol; ACh Binding Site, the putative ACh binding site; Intra-subunit, site between
subunits in the transmembrane domain of 42; Near Cys Loop, site that is near the Cys loop of 42; Channel Pore, site that is in the channel pore of
42; Interfacial, a site on the transmembrane domain of a single subunit that faces toward the other transmembrane domain helices on the same subunit.
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Discussion
Throughout the history of menthol-flavored tobacco
products, various methods have been used to obtain the
menthol used in cigarette production. Isolations from nat-
ural sources (mint leaves and oils) primarily produce ()-
menthol; most synthetic methods produce a racemic
mixture of both ()-menthol and ()-menthol. The excep-
tion is the asymmetric synthesis developed by Ohkuma
et al. (2000). We found that ()-menthol and ()-menthol
exhibit different effects on 42 nAChR upregulation (Fig.
1). We also observed differences among the menthol
stereoisomers in their ability to alter dopamine neuron
firing frequency and excitability (Figs. 2, 3). Our previous
investigations into the actions menthol used ()-menthol
(Henderson et al., 2016, 2017). Previous reports observed
that ()-menthol by itself upregulated nAChRs, altered
dopamine neuron firing, enhanced the upregulation of
nicotine-induced nAChR upregulation, and enhanced nic-
otine reward-related behavior. Because the present inves-
tigation shows that ()-menthol has no effect on nAChR
upregulation and dopamine neuron excitability, we con-
clude that previous observations of long-term menthol
exposure and its effect on nAChR upregulation and do-
pamine neuron excitability were likely caused primarily by
()-menthol only.
Because of the contrast between the high concentra-
tion of menthol required for acute inhibition of nAChRs
(30 M) and the submicromolar effects on upregulation
and dopamine neuron firing ( 500 nM), it is likely that
menthol acts via multiple targets. The simulations and
Figure 7. 4L9´ mutations probe the putative binding site of menthol. A1, A2, Concentration–response curves for menthol against
(4[L9´X])2(2)3, where X is any amino acid. Each receptor is activated by its respective EC50 dose of ACh (A1) ()-menthol and (A2)
()-menthol. B, Concentration–response curves for (4[L9´X])3(2)2 and (4)3(2)2 using 1 M ACh. C, Comparing the percentage
maximum current induced when the oocyte is exposed to 100 M menthol. p
 0.05; p
 0.01; p
 0.005; p
 0.001. Exact
p values are provided in extended data (Fig. 7-1). D1, Comparing the IC50 values. In this plot, (4[L9´A])2(2)3 is omitted because at
no tested concentration of menthol was the receptor inhibited 50%. D2, Plot of IC30 values comparing ()-menthol and ()-menthol;
n 	 6–18 oocytes.
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data in this study strongly suggest that the acute inhibi-
tory effect of menthol is mediated through its direct inter-
action with nAChRs at the 9´ leucine site within the TM2
region. In previous electrophysiological experiments, well
characterized nAChR blockers have permanent positive
charges (e.g., QX-222) or can be protonated (e.g.,
mecamylamine) and bind near this site (at the 6´ and 10´
positions) by approaching through the open pore (Charnet
et al., 1990; Lester, 1992; Papke et al., 2013). However, other
experiments suggest that uncharged, membrane-permeant
blockers, such as deprotonated procaine, can bind to the 6´
and 10´ residues in closed channels by approaching through
the membrane or through the receptor protein (Adams,
1977; Lester, 1992). The simulations in this study reinforce
the concept that menthol approaches the 9´ site in closed
42 nAChR channels by approaching from the protein. Our
simulations are uninformative about a possible approach
from the membrane phase, because the parameters were
adjusted to minimize accumulation in the membrane phase
(see Materials and Methods).
The experiments also show that ()-menthol is only
slightly (25%) more effective than ()-menthol at inhibiting
WT receptors (Fig. 4). This difference would be neglected if
the dataset contained only WT receptors, but it is consistent
and significant when assessed over a series of 9´ mutations
that encompass a nearly 1000-fold range of sensitivities to
menthol block (Fig. 7D1,D2). S()mecamylamine is a slightly
more potent blocker than R()mecamylamine over a series
of nAChR subtypes (Papke et al., 2013). These differences
between stereoisomers as nAChR blockers are markedly
less than the threefold to fourfold greater potency of ()-
menthol versus ()-menthol at TRPM8 channels (Sherkheli
et al., 2010).
The submicromolar chronic effects of menthol may re-
sult from a non-nAChR target. In addition to its actions on
nAChRs, menthol acts as a positive modulator on GABAA
and glycine receptors and a noncompetitive antagonist of
5-HT3 receptors (Hall et al., 2004; Ashoor et al., 2013a).
Menthol has well studied actions on TRP family proteins,
especially TRPM8 and TRPA1 (Oz et al., 2017). Menthol
also acts on other targets (Oz et al., 2017). Therefore,
while menthol has acute actions on nAChRs (noncompet-
itive inhibition) through an allosteric interaction at the 9´
site, its effects on nAChR upregulation and dopamine
neuron excitability may be caused by another protein
target. Previous investigators suggested that menthol
acts as a chemical chaperone (Henderson et al., 2016), in
part because menthol enhanced the ER export of
nAChRs. This designation has both analogies and differ-
ences with the pharmacological chaperoning of nAChRs
by nicotine (Kuryatov et al., 2005; Srinivasan et al., 2011).
Menthol may indeed be a chemical chaperone for
nAChRs; but, given its ability to bind to many proteins of
interest, we must consider that the enhancement of ER
export by menthol may arise from its actions on a non-
nAChR target related to anterograde trafficking of pro-
teins or membranes.
As discussed earlier, menthol enhances nicotine reward
(Henderson et al., 2017) and nicotine reinforcement
(Wang et al., 2014; Biswas et al., 2016) in rodent models
and produces poorer cessation rates in human smokers
(Food and Drug Administration, 2012). Although the pre-
dominant form present in current tobacco products is
()-menthol, the composition of menthol used in many
tobacco products is presently neither disclosed nor reg-
ulated. For this reason, it is important to understand how
both ()-menthol and ()-menthol alter the nAChRs on
dopamine neurons that are involved in nicotine reward
and reinforcement. This is especially important given that
the ENDS market will become subject to systematic reg-
ulatory control by the Food and Drug Administration. Our
data suggest that menthol exhibits a stereospecific effect
only with low-dose, long-term exposure. We hypothesize
that of the two primary menthol stereoisomers, only ()-
menthol plays a role in enhancing nicotine reward through
nAChRs on dopamine neurons. We do not yet suggest
that ()-menthol lacks any role in nicotine reward. GABA
neurons in the VTA and SNr play an important role in
nicotine reward as their disinhibition plays a critical role in
the ability of nicotine to drive enhancements, dopamine
neuron excitability, and dopamine release (Mansvelder
et al., 2002; Nashmi et al., 2007). Menthol does act as a
positive allosteric modulator of GABAA receptors and ()-
menthol is more potent than ()-menthol on these recep-
Figure 8. A, The ratio of currents elicited by an EC50 concentration of ACh and 100 M menthol over the current elicited by ACh alone.
Error bars represent the SEM; n 	 7-33 oocytes. B, Average Hill coefficients for wild-type and all mutant 42 mutants tested (p 	
0.07). Error bars represent the SD; n 	 7-39 mutants
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tors (Hall et al., 2004; Corvalán et al., 2009). Given that
stereospecific effects of menthol have been observed
with nAChRs and GABA receptors (both important targets
for nicotine reward), there is a continued need to under-
stand their distinct pharmacology and how it alters the
actions of nicotine on midbrain neurons.
Given the reduced effect ()-menthol exhibits on
dopamine neurons, would public health benefit from
availability of combustible products in which ()-
menthol replaces ()-menthol? Because ()-menthol
is also less effective at activating TRPM8, ()-
mentholated products might also less effectively pro-
vide the characteristic cooling sensation. Smokers
might therefore continue to prefer tobacco flavored
with ()-menthol (Sherkheli et al., 2010). We also have
no information about stereospecificity of TRPA1 activa-
tion by either menthol or nicotine (Talavera et al., 2009).
This report, and others (Alsharari et al., 2015; Biswas
Figure 9. Potency of menthol depends on L9´ residue size. A1–B2, Plot of IC40 for ()-menthol versus residue length (A1) or residue
volume (B1) and plot of IC30 for ()-menthol versus residue length (A2) or residue volume (B2). C1, Fitting the IC40 values for
()-menthol against the reduced AA index. C2, Fitting the IC30 values for ()-menthol against the reduced AA index. R
2 values in C1
and C2 for each parameter are indicated in Figure 9-1 and Figure 9-2. D, Concentration–response relationship for ()-menthol on
(4[L9´I])3(2)2 and (4[L9´O-Me-Thr])3(2)2 nAChRs. Structures of the two amino acids are shown to the left along with their
end-to-end length; n 	 7–18 oocytes.
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et al., 2016; Fan et al., 2016; Henderson et al., 2016,
2017), provide evidence both that ()-menthol plays a
role in enhancing the addiction to nicotine, and also
that simply substituting ()-menthol for ()-menthol in
combustible tobacco products may not be the correct
strategy for harm reduction.
References
Adams PR (1977) Voltage jump analysis of procaine action at frog
end-plate. J Physiol 268:291–318. CrossRef Medline
Ahijevych K, Garrett BE (2010) The role of menthol in cigarettes as a
reinforcer of smoking behavior. Nicotine Tob Res 12:S110–S116.
CrossRef Medline
Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu
AZX, Tyndale RF, Kabbani N, Damaj MI (2015) Effects of menthol
on nicotine pharmacokinetic, pharmacology and dependence in
mice. PLoS One 10:e0137070. CrossRef Medline
Arcario MJ, Mayne CG, Tajkhorshid E (2017) A membrane-
embedded pathway delivers general anesthetics to two interacting
binding sites in the Gloeobacter violaceus ion channel. J Biol
Chem 292:9480–9492. CrossRef Medline
Ashoor A, Nordman JC, Veltri D, Yang KHS, Shuba Y, Al Kury L,
Sadek B, Howarth FC, Shehu A, Kabbani N, Oz M (2013a) Menthol
inhibits 5-HT3 receptor-mediated currents. J Pharmacol Exp Ther
347:398–409. CrossRef Medline
Ashoor A, Nordman JC, Veltri D, Yang KH, Al Kury L, Shuba Y,
Mahgoub M, Howarth FC, Sadek B, Shehu A, Kabbani N, Oz M
(2013b) Menthol binding and inhibition of 7-nicotinic acetylcho-
line receptors. PLoS One 8:e67674. CrossRef Medline
Biswas L, Harrison E, Gong YZ, Avusula R, Lee J, Zhang MY,
Rousselle T, Lage J, Liu X (2016) Enhancing effect of menthol on
nicotine self-administration in rats. Psychopharmacology 233:
3417–3427. CrossRef Medline
Bottaro S, Lindorff-Larsen K (2018) Biophysical experiments and
biomolecular simulations: a perfect match? Science 361:355–360.
CrossRef Medline
Brannigan G, LeBard DN, Hénin J, Eckenhoff RG, Klein ML (2010)
Multiple binding sites for the general anesthetic isoflurane identi-
fied in the nicotinic acetylcholine receptor transmembrane domain.
Proc Natl Acad Sci U S A 107:14122–14127. CrossRef Medline
Centers for Disease Control and Prevention (2016) Tobacco use
among middle and high school students-United States, 2011-
2015. MMWR Morb Mortal Wkly Rep 65:361–367. CrossRef Med-
line
Charnet P, Labarca C, Leonard RJ, Vogelaar NJ, Czyzyk L, Gouin A,
Davidson N, Lester HA (1990) An open-channel blocker interacts
with adjacent turns of alpha-helices in the nicotinic acetylcholine
receptor. Neuron 4:87–95. CrossRef Medline
Chen C, Luo W, Isabelle LM, Gareau KD, Pankow JF (2011) The
stereoisomers of menthol in selected tobacco products. A brief
report. Nicotine Tob Res 13:741–745. CrossRef Medline
Corvalán NA, Zygadlo JA, García DA (2009) Stereo-selective activity
of menthol on GABA(A) receptor. Chirality 21:525–530. CrossRef
Medline
D’Silva J, Boyle RG, Lien R, Rode P, Okuyemi KS (2012) Cessation
outcomes among treatment-seeking menthol and nonmenthol
smokers. Am J Prev Med 43:S242–S248. CrossRef
Dalton JA, Gómez-Santacana X, Llebaria A, Giraldo J (2014) Com-
putational analysis of negative and positive allosteric modulator
binding and function in metabotropic glutamate receptor 5 (in)ac-
tivation. J Chem Inf Model 54:1476–1487. CrossRef
Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an
N·log(N) method for Ewald sums in large systems. J Chem Phys
98:10089–10092. CrossRef
Dash B, Li MD, Lukas RJ (2014) Roles for N-terminal extracellular
domains of nicotinic acetylcholine receptor (nAChR) 3 subunits in
enhanced functional expression of mouse 623- and 643-
nAChRs. J Biol Chem 289:28338–28351. CrossRef Medline
Drenan RM, Nashmi R, Imoukhuede P, Just H, McKinney S, Lester
HA (2008) Subcellular trafficking, pentameric assembly, and sub-
unit stoichiometry of neuronal nicotinic acetylcholine receptors
containing fluorescently labeled alpha6 and beta3 Subunits. Mol
Pharmacol 73:27–41. CrossRef Medline
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG
(1995) A smooth particle mesh Ewald method. J Chem Phys
103:8577–8593. CrossRef
Fan L, Balakrishna S, Jabba SV, Bonner PE, Taylor SR, Picciotto MR,
Jordt SE (2016) Menthol decreases oral nicotine aversion in
C57BL/6 mice through a TRPM8-dependent mechanism. Tob
Control 25:ii50–ii54. CrossRef Medline
Food and Drug Administration (2012) Preliminary scientific evaluation
of the possible public health effects of menthol versus nonmenthol
cigarettes. Silver Spring, MD: Food and Drug Administration.
Gusain P, Ohki S, Hoshino K, Tsujino Y, Shimokawa N, Takagi M
(2017) Chirality-dependent interaction of D- and L-menthol with
biomembrane models. Membranes 7:13.
Ha MA, Smith GJ, Cichocki JA, Fan L, Liu YS, Caceres AI, Jordt SE,
Morris JB (2015) Menthol attenuates respiratory irritation and ele-
vates blood cotinine in cigarette smoke exposed mice. PLoS One
10:e0117128. CrossRef Medline
Hall AC, Turcotte CM, Betts BA, Yeung WY, Agyeman AS, Burk LA
(2004) Modulation of human GABA(A) and glycine receptor cur-
rents by menthol and related monoterpenoids. Eur J Pharmacol
506:9–16. CrossRef Medline
Hans M, Wilhelm M, Swandulla D (2012) Menthol suppresses nico-
tinic acetylcholine receptor functioning in sensory neurons via
allosteric modulation. Chem Senses 37:463–469. CrossRef Med-
line
Heck JD (2010) A review and assessment of menthol employed as a
cigarette flavoring ingredient. Food Chem Toxicol 48 [Suppl. 2]:
S1–38. CrossRef Medline
Henderson BJ, Srinivasan R, Nichols WA, Dilworth CN, Gutierrez DF,
Mackey EDW, McKinney S, Drenan RM, Richards CI, Lester HA
(2014) Nicotine exploits a COPI-mediated process for chaperone-
mediated up-regulation of its receptors. J Gen Physiol 143:51–66.
CrossRef Medline
Henderson BJ, Wall TR, Henley BM, Kim CH, Nichols WA, Moaddel
R, Xiao C, Lester HA (2016) Menthol alone upregulates midbrain
nAChRs, alters nAChR subtype stoichiometry, alters dopamine
neuron firing frequency, and prevents nicotine reward. J Neurosci
36:2957–2974. CrossRef Medline
Henderson BJ, Wall TR, Henley BM, Kim CH, McKinney S, Lester HA
(2017) Menthol enhances nicotine reward-related behavior by po-
tentiating nicotine-induced changes in nAChR function, nAChR
upregulation, and DA neuron excitability. Neuropsychopharmacol-
ogy 42:2285–2291. CrossRef Medline
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular
dynamics. J Mol Graph Model 14:33–38. CrossRef Medline
Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based
graphical user interface for CHARMM. J Comput Chem 29:1859–
1865. CrossRef Medline
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML
(1983) Comparison of simple potential functions for simulating
liquid water. J Chem Phys 79:926–935. CrossRef
Kearney PC, Zhang HY, Zhong W, Dougherty DA, Lester HA (1996)
Determinants of nicotinic receptor gating in natural and unnatural
side chain structures at the M2 9´ position. Neuron 17:1221–1229.
CrossRef
Kibinge N, Ikeda S, Ono N, Altaf-Ul-Amin M, Kanaya S (2014) Inte-
gration of residue attributes for sequence diversity characteriza-
tion of terpenoid enzymes. Biomed Res Int 2014:753428. CrossRef
Medline
Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ,
Mondragon-Ramirez C, Vorobyov I, MacKerell AD, Pastor RW
(2010) Update of the CHARMM all-atom additive force field for
lipids: validation on six lipid types. J Phys Chem B 114:7830–
7843. CrossRef Medline
New Research 18 of 19
November/December 2018, 5(6) e0465-18.2018 eNeuro.org
Kosolapov AV, Filatov GN, White MM (2000) Acetylcholine receptor
gating is influenced by the polarity of amino acids at position 9´ in
the M2 domain. J Membr Biol 174:191–197. CrossRef Medline
Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a
pharmacological chaperone to up-regulate human alpha4beta2
acetylcholine receptors. Mol Pharmacol 68:1839–1851. CrossRef
Medline
Labarca C, Nowak MW, Zhang HY, Tang LX, Deshpande P, Lester
HA (1995) Channel gating governed symmetrically by conserved
leucine residues in the M2 domain of nicotinic receptors. Nature
376:514–516. CrossRef Medline
Lau BK, Vaughan CW (2014) Descending modulation of pain: the
GABA disinhibition hypothesis of analgesia. Curr Opin Neurobiol
29:159–164. CrossRef Medline
Lester HA (1992) The permeation pathway of neurotransmitter-gated
ion channels. Annu Rev Biophys Biomol Struct 21:267–292.
CrossRef Medline
Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mecha-
nisms underlie nicotine-induced excitability of brain reward areas.
Neuron 33:905–919. CrossRef Medline
Marotta CB, Dilworth CN, Lester HA, Dougherty DA (2014) Probing
the non-canonical interface for agonist interaction with an 5
containing nicotinic acetylcholine receptor. Neuropharmacology
77:342–349. CrossRef Medline
McCarthy WJ, Caskey NH, Jarvik ME, Gross TM, Rosenblatt MR,
Carpenter C (1995) Menthol vs nonmenthol cigarettes: effects on
smoking-behavior. Am J Public Health 85:67–72. CrossRef Med-
line
Morales-Perez CL, Noviello CM, Hibbs RE (2016) X-ray structure of
the human 42 nicotinic receptor. Nature 538:411–415. CrossRef
Medline
Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker
P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins
AC, Marks MJ, Lester HA (2007) Chronic nicotine cell specifically
upregulates functional alpha 4 nicotinic receptors: basis for both
tolerance in midbrain and enhanced long-term potentiation in
perforant path. J Neurosci 27:8202–8218. CrossRef Medline
Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J (2003) Alter-
nate stoichiometries of alpha4beta2 nicotinic acetylcholine recep-
tors. Mol Pharmacol 63:332–341. CrossRef Medline
Ohkuma T, Ishii D, Takeno H, Noyori R (2000) Asymmetric hydroge-
nation of amino ketones using chiral RuCl2(diphophine)(1,2-
diamine) complexes. J Am Chem Soc 122:6510–6511. CrossRef
Oz M, El Nebrisi EG, Yang KS, Howarth FC, Al Kury LT (2017) Cellular
and molecular targets of menthol actions. Front Pharmacol 8:472.
CrossRef Medline
Papke RL, Stokes C, Muldoon P, Imad Damaj M (2013) Similar
activity of mecamylamine stereoisomers in vitro and in vivo. Eur J
Pharmacol 720:264–275. CrossRef Medline
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E,
Chipot C, Skeel RD, Kalé L, Schulten K (2005) Scalable molecular
dynamics with NAMD. J Comput Chem 26:1781–1802. CrossRef
Medline
Prinz H (2010) Hill coefficients, dose–response curves and allosteric
mechanisms. J Chem Biol 3:37–44. CrossRef Medline
Richards CI, Srinivasan R, Xiao C, Mackey EDW, Miwa JM, Lester HA
(2011) Trafficking of alpha4 nicotinic receptors revealed by su-
perecliptic phluorin: effects of a beta4 amyotrophic lateral
sclerosis-associated mutation and chronic exposure to nicotine. J
Biol Chem 286:31241–31249. CrossRef Medline
Sánchez R, Sali A (1998) Large-scale protein structure modeling of
the Saccharomyces cerevisiae genome. Proc Natl Acad Sci U S A
95:13597–13602. CrossRef Medline
Sell CS (2006) The chemistry of fragrances: from perfumer to con-
sumer. Cambridge, UK: Royal Society of Chemistry.
Sherkheli MA, Vogt-Eisele AK, Bura D, Beltrán Márques LR, Gissel-
mann G, Hatt H (2010) Characterization of selective TRPM8 li-
gands and their structure activity response (S.A.R.) relationship. J
Pharm Pharm Sci 13:242–253. CrossRef
Srinivasan R, Pantoja R, Moss FJ, Mackey EDW, Son CD, Miwa J,
Lester HA (2011) Nicotine up-regulates 42 nicotinic receptors
and ER exit sites via stoichiometry-dependent chaperoning. J Gen
Physiol 137:59–79. CrossRef Medline
Srinivasan R, Henley BM, Henderson BJ, Indersmitten T, Cohen BN,
Kim CH, McKinney S, Deshpande P, Xiao C, Lester HA (2016)
Smoking-relevant nicotine concentration attenuates the unfolded
protein response in dopaminergic neurons. J Neurosci 36:65–79.
CrossRef Medline
Takai Y, Touhara K (2015) Enantioselective recognition of menthol by
mouse odorant receptors. Biosci Biotechnol Biochem 79:1980–
1986. CrossRef Medline
Talavera K, Gees M, Karashima Y, Meseguer VM, Vanoirbeek JA,
Damann N, Everaerts W, Benoit M, Janssens A, Vennekens R,
Viana F, Nemery B, Nilius B, Voets T (2009) Nicotine activates the
chemosensory cation channel TRPA1. Nat Neurosci 12:1293–
1299. CrossRef Medline
Tapia L, Kuryatov A, Lindstrom J (2007) Ca2 permeability of
the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of
(alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol
71:769–776. CrossRef Medline
Ton HT, Smart AE, Aguilar BL, Olson TT, Kellar KJ, Ahern GP (2015)
Menthol enhances the desensitization of human 34 nicotinic
acetylcholine receptors. Mol Pharmacol 88:256–264. CrossRef
Medline
Vanommeslaeghe K, MacKerell AD (2012) Automation of the
CHARMM general force field (CGenFF) I: bond perception and
atom typing. J Chem Inf Model 52:3144–3154. CrossRef Medline
Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim
J, Darian E, Guvench O, Lopes P, Vorobyov I, MacKerell AD (2010)
CHARMM general force field: a force field for drug-like molecules
compatible with the CHARMM all-atom additive biological force
fields. J Comput Chem 31:671–690. CrossRef Medline
Vanommeslaeghe K, Raman EP, MacKerell AD (2012) Automation of
the CHARMM general force field (CGenFF) II: assignment of
bonded parameters and partial atomic charges. J Chem Inf Model
52:3155–3168. CrossRef Medline
Wang TF, Wang B, Chen H (2014) Menthol facilitates the intravenous
self-administration of nicotine in rats. Front Behav Neurosci 8:437.
CrossRef Medline
Yu WB, He XB, Vanommeslaeghe K, MacKerell AD (2012) Extension
of the CHARMM general force field to sulfonyl-containing com-
pounds and its utility in biomolecular simulations. J Comput Chem
33:2451–2468. CrossRef Medline
Zamyatnin AA (1972) Protein volume in solution. Prog Biophys Mol
Biol 24:107–123. CrossRef Medline
New Research 19 of 19
November/December 2018, 5(6) e0465-18.2018 eNeuro.org
